Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine disorders, rose 17% as of 11:45 a.m. EDT Thursday.
Here's a review of the key takeaways from the company's third quarter:
Commenting on the quarter, CEO Kevin Gorman stated:
Source: Fool.com
Neurocrine Bioscience Aktie
132,00 €
-0,65 %
Absolute Beliebtheit: Neurocrine Bioscience hat nur Buy-Einschätzungen.
Ein Kursziel von 160 € für Neurocrine Bioscience könnte zu einer Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 132.0 € führen.
